Federated Hermes, INC Schedule 13G passive stakes

Federated Hermes, Inc. and related entities report a 4.03% beneficial ownership stake in SCYNEXIS Inc. as of June 30, 2026.

Federated Hermes, Inc. and associated entities report a 4.45% beneficial ownership stake in SCYNEXIS Inc. common stock as of June 30, 2026.

Federated Hermes, Inc. and related entities have filed a Schedule 13G, reporting beneficial ownership of 4.15% of Ovid Therapeutics Inc. common stock as of June 30, 2026.

Federated Hermes, Inc. and associated entities have filed a Schedule 13G, reporting beneficial ownership of 17.17% of Minerva Neurosciences, Inc. common stock as of June 30, 2026.

Federated Hermes, Inc. and associated entities report a beneficial ownership stake of 4.59% in MGP Ingredients, Inc. as of June 30, 2026.

Federated Hermes, Inc. and related entities have reported beneficial ownership of 5.68% of LifeMD, Inc. common stock as of June 30, 2026.

Federated Hermes, Inc. and related entities have filed a Schedule 13G, reporting beneficial ownership of 10.31% of Forte Biosciences, Inc. common stock as of June 30, 2026.

Federated Hermes, Inc. and associated entities have filed an amended Schedule 13G, reporting beneficial ownership of 8,509,678 shares, representing 8.68% of aTyr Pharma Inc.'s common stock.

Vanguard Portfolio Management has disclosed a beneficial ownership of 4,603,965 shares, representing 6.06% of Federated Hermes Inc.'s common stock as of March 31, 2026.

Federated Hermes, Inc. and associated entities have reported a decreased beneficial ownership in SoundThinking, Inc., now holding 450,000 shares.

Federated Hermes, Inc. and associated entities reported a passive ownership stake of 2.86% in Smith Douglas Homes Corp. as of March 31, 2026.

Federated Hermes, Inc. and associated entities have disclosed a passive ownership stake of 5.59% in MGP Ingredients Inc, representing over 1.19 million shares.

Federated Hermes, Inc. has reported a passive ownership stake of 5.06% in Advance Auto Parts Inc, totaling over 3 million shares.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Federated Hermes Inc. following an internal realignment.

Federated Hermes, Inc. and related entities have reported a 5.24% beneficial ownership stake in TTEC Holdings, Inc. common stock as of December 31, 2025.

Federated Hermes, Inc. and related entities have reported a 5.94% beneficial ownership stake in Ovid Therapeutics Inc. common stock as of December 31, 2025.

Federated Hermes, Inc. and related entities have filed an amendment to their Schedule 13G, reporting a beneficial ownership of 8.42% of SCYNEXIS, INC. common stock.

Federated Hermes, Inc. and affiliated entities reported a 6.75% beneficial ownership stake in MGP Ingredients, Inc. common stock as of December 31, 2025.

Federated Hermes, Inc. and affiliated entities have reported a reduced beneficial ownership in IDEAYA Biosciences, Inc. to 3.87% of common stock.

Federated Hermes, Inc. and related entities filed an amendment to their Schedule 13G, disclosing a continued beneficial ownership of 11.63% in Arcturus Therapeutics Holdings Inc.

Federated Hermes and related entities have reclassified their nearly 20% stake in Minerva Neurosciences, Inc. from active influence to a passive investment.

Federated Hermes, Inc. and related entities have reported a 5.17% beneficial ownership stake in MGP Ingredients Inc. common stock, held for investment purposes.

Federated Hermes, Inc. and related entities reported a 7.82% beneficial ownership stake in SOUNDTHINKING, INC. common stock through a Schedule 13G filing.

Federated Hermes, Inc. and its affiliated entities reported beneficial ownership of 11.26% of SCYNEXIS INC's common stock, totaling 5,116,598 shares.

Federated Hermes, Inc., along with its affiliates and the Donahue family, disclosed a 13.15% beneficial ownership stake in Forte Biosciences, Inc. common stock.

Federated Hermes, Inc. and affiliated entities reported continued beneficial ownership of 10.76% of aTYR Pharma Inc.'s common stock as a passive investor.

Federated Hermes, Inc. and related entities have filed an amended Schedule 13G, disclosing beneficial ownership of 1,478,647 shares, representing 11.89% of Forte Biosciences, Inc.'s common stock.

Federated Hermes, Inc. and affiliated entities have disclosed a passive beneficial ownership of 8.78% in Forte Biosciences, Inc. common stock as of June 30, 2025.

Federated Hermes, Inc. and affiliated entities have disclosed a 6.68% beneficial ownership stake in EyePoint Pharmaceuticals, Inc., held in the ordinary course of business.

Federated Hermes, Inc., along with the Voting Shares Irrevocable Trust and its trustees, has filed an amended Schedule 13G disclosing a passive beneficial ownership of 0.51% in Virgin Galactic Holdings, Inc.